PRESS RELEASE. Sciety’s portfolio company TIRmed Pharma has strengthened its board with the appointment of Peder Walberg – a strategic addition as the company advances the development of a promising new treatment for atopic dermatitis (eczema). The appointment is the result of a targeted recruitment process carried out in close collaboration between TIRmed and Sciety, where Walberg’s experience was seen as particularly valuable in preparation for the company’s upcoming Phase Ib clinical trial.
TIRmed is developing a next generation treatment for atopic dermatitis, with the ambition to offer patients an effective therapy with fewer side effects and easier administration.
Unlike existing therapies that mainly relieve symptoms, TIRmed’s treatment targets the underlying causes of the disease. Preclinical results have been highly promising – just five applications over two weeks have delivered relief lasting up to 15 months. The addition of Peder Walberg strengthens the board at a critical time, as TIRmed prepares to enter clinical trials.
Peder Walberg is a licensed physician and economist, currently active as an investor and advisor in the life science sector. He also serves on the board of Immedica Pharma AB. Walberg brings a long and accomplished career in life sciences, with extensive experience in driving drug development and commercialisation. During his time at Novartis, he was responsible for the Swedish launch of Elidel, a treatment for atopic dermatitis. He has played key roles in strategic decision-making, regulatory considerations, and negotiations with licensing partners and acquirers. His previous roles include senior positions at Sobi, Wilson Therapeutics, Immedica Pharma AB, and Egetis Therapeutics.
The board recruitment was carried out by TIRmed in close dialogue with Sciety, who identified Walberg as a strong candidate to support both the clinical development of the company’s drug candidate and its broader strategic and commercial progress.
“We are very pleased to welcome Peder Walberg to the board. His experience in building value in pharmaceutical companies – from clinical development through to market launch – will be invaluable to TIRmed as we move into our upcoming clinical trial,” says Leo Holmgren, CEO of TIRmed Pharma.
“Peder Walberg brings experience that complements the existing board in a highly valuable way. His strategic and commercial expertise is particularly important at this stage of the company’s journey – where making the right decisions around study design and regulatory strategy will lay the foundation for strong positioning and future commercialisation. Helping to identify the right board expertise is a key part of how we at Sciety work in close partnership with our portfolio companies,” says Andreas Lindblom, Managing Partner at Sciety.
The appointment of Peder Walberg strengthens TIRmed’s board both operationally and strategically, and marks an important step in the company’s preparations for further clinical studies and future commercialisation.
For further information, please contact:
Andreas Lindblom, Managing Partner, Sciety: andreas.lindblom@sciety.se, phone: +46 70 375 73 73.
Leo Holmgren, CEO, TIRmed Pharma, leo.holmgren@tirmedpharma.com, phone: +46 70 049 18 42
_________________________________________________
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing the next generation of immunomodulatory treatments for autoimmune skin diseases, with a focus on atopic dermatitis (eczema). The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates the immune system and addresses the underlying causes of the disease. Preclinical results demonstrate the treatments potential to provide long-lasting relief and reduce treatment burden. TIRmed Pharma is headquartered in Stockholm. For more information, visit tirmedpharma.com and follow TIRmed on Linkedin.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information visit sciety.com and follow Sciety on Linkedin.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
Latest news
